secwatch.observer — SEC 8-K summary
======================================

Issuer:     AXIM BIOTECHNOLOGIES, INC. (AXIM)
CIK:        0001514946
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001096906-21-001784
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AXIM Biotech signs binding term sheet to acquire FDA-cleared dry eye tests, paying 7M shares
--------------------------------------------------------------------------------

- AXIM to acquire two FDA-cleared dry eye diagnostic tests from Advanced Tear Diagnostics for 7M restricted shares.
- Tests include 10-minute lactoferrin assay and ocular IgE test; commercial launch targeted for early 2022.
- Dry eye disease affects ~20M in US; global DED diagnostics market projected at $9.8B by 2030.
- Binding term sheet in effect; definitive agreement and closing expected by October 1, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/0001096906-21-001784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/axim-20210802.htm
  HTML page:      https://secwatch.observer/filing/0001096906-21-001784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer